Highlights

  • Third quarter net loss was USD 53.9 million, or USD 0.82 per share.
  • Cash, restricted cash and marketable securities were USD 558.9 million.
  • Third quarter R&D expenses fell to USD 46.9 million from USD 64.7 million.
  • The next clinical update is expected in mid-2027.

Arvinas, Inc. (NASDAQ:ARVN) shares were trading near their 52-week low at USD 6.51 on November 6, 2026, down 0.61% on the day. The clinical stage company reported a third quarter net loss of USD 53.9 million, or USD 0.82 per share, and USD 558.9 million in cash equivalents, restricted cash and marketable securities.

Arvinas has a market Capitalization of about USD 426.31 million at the current price. It is a clinical stage biotechnology company pioneering a new class of medicines through its PROTAC protein degradation platform.

Third Quarter Results

Revenue was USD 0.5 million against USD 41.9 million. Total operating expenses were USD 59.6 million against USD 85.7 million, and the loss from operations was USD 59.1 million against USD 43.8 million. The net loss was USD 53.9 million against USD 35.1 million, and the loss per share was USD 0.82 against USD 0.48.

Management said R&D expenses were USD 46.9 million against USD 64.7 million, and general and administrative expenses were USD 12.6 million against USD 21 million. Non-GAAP R&D expenses were down USD 12.6 million, or 22%, and non-GAAP expenses were USD 53.5 million against USD 71.5 million.

Nine-Month Results

Revenue was USD 265.8 million against USD 253.1 million. Total operating expenses were USD 224.6 million against USD 297.0 million, and income from operations was USD 41.2 million against a loss of USD 43.9 million. Net Income was USD 57.9 million against a net loss of USD 13.4 million, and Diluted Earnings per Share were USD 0.88 against a loss of USD 0.18.

Pipeline

Management said the first of two data readouts for its lymphoma program is complete and that the next update, expected in mid-2027, will include more patients with B-cell lymphoma treated at doses in the predicted efficacious range, longer follow up, and initial combination data with glofitamab.

Cash Flow and Balance Sheet

Cash and cash equivalents were USD 88.0 million against USD 142.9 million at December 31, 2025. Management put cash equivalents, restricted cash and marketable securities at USD 558.9 million against USD 685.4 million at the end of 2025. For the nine months, net cash used in Operating Activities was USD 127.9 million against USD 243.4 million, and net cash provided by financing activities was USD 0.7 million against cash used of USD 17.4 million.

Total Assets were USD 607.5 million against USD 717.9 million. Total liabilities were USD 93.7 million against USD 284.0 million, and total stockholders' Equity was USD 513.8 million against USD 433.9 million. The accumulated Deficit was USD 1,554.5 million. There were 65,485,006 shares outstanding as of October 30, 2026.